The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of eNOS polymorphisms with clinical outcome in bevacizumab-treated breast cancer patients.
Marzia Del Re
No relevant relationships to disclose
Andrea Fontana
No relevant relationships to disclose
Daniele Giulio Generali
No relevant relationships to disclose
Barbara Pistilli
No relevant relationships to disclose
Valentina Citi
No relevant relationships to disclose
Paola Ulivi
No relevant relationships to disclose
Wainer Zoli
No relevant relationships to disclose
Eleonora Bona
No relevant relationships to disclose
Barbara Salvadori
No relevant relationships to disclose
Ilaria Ferrarini
No relevant relationships to disclose
Elisabetta Landucci
No relevant relationships to disclose
Sara Fancelli
No relevant relationships to disclose
Ilaria Bertolini
No relevant relationships to disclose
Andrea Michelotti
No relevant relationships to disclose
Luciano Latini
No relevant relationships to disclose
Alberto Bottini
No relevant relationships to disclose
Alfredo Falcone
No relevant relationships to disclose
Romano Danesi
No relevant relationships to disclose